HPA003456

antibody from Atlas Antibodies

Targeting: ZEB2 KIAA0569, SIP-1, SIP1, ZFHX1B

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Chromatin Immunoprecipitation (Supportive data in Antibodypedia)

Antibody Data

Product number

HPA003456

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA003456, RRID:AB_10603840

Product name

Anti-ZEB2

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human ZEB2, Gene description: zinc finger E-box binding homeobox 2, Alternative Gene Names: KIAA0569, SIP-1, SIP1, ZFHX1B, Validated applications: WB, IHC, ChIP, Uniprot ID: O60315, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.2 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Cancer Cell Biomechanical Properties Accompany Tspan8-Dependent Cutaneous Melanoma Invasion

Runel G, Lopez-Ramirez N, Barbollat-Boutrand L, Cario M, Durand S, Grimont M, Schartl M, Dalle S, Caramel J, Chlasta J, Masse I
Cancers 2024;16(4):694

---

Cooperative pro-tumorigenic adaptation to oncogenic RAS through epithelial-to-mesenchymal plasticity

De Blander H, Tonon L, Fauvet F, Pommier R, Lamblot C, Benhassoun R, Angileri F, Gibert B, Rodriguez R, Ouzounova M, Morel A, Puisieux A
Science Advances 2024;10(7)

---

An in vivo avian model of human melanoma to perform rapid and robust preclinical studies

Jarrosson L, Dalle S, Costechareyre C, Tang Y, Grimont M, Plaschka M, Lacourrège M, Teinturier R, Le Bouar M, Maucort‐Boulch D, Eberhardt A, Castellani V, Caramel J, Delloye‐Bourgeois C
EMBO Molecular Medicine 2023;15(3)

---

Differentiation‐related epigenomic changes define clinically distinct keratinocyte cancer subclasses

Solé‐Boldo L, Raddatz G, Gutekunst J, Gilliam O, Bormann F, Liberio M, Hasche D, Antonopoulos W, Mallm J, Lonsdorf A, Rodríguez‐Paredes M, Lyko F
Molecular Systems Biology 2022;18(9)

---

Expression of Selected Epithelial‐Mesenchymal Transition Transcription Factors in Endometrial Cancer

Sadłecki P, Jóźwicki J, Antosik P, Walentowicz-Sadłecka M, Todorov P
BioMed Research International 2020;2020(1)

---

Potassium usnate, a water-soluble usnic acid salt, shows enhanced bioavailability and inhibits invasion and metastasis in colorectal cancer

Yang Y, Bae W, Lee J, Choi Y, Lee K, Park M, Yu Y, Park S, Zhou R, Taş İ, Gamage C, Paik M, Lee J, Chung I, Kim K, Hur J, Kim S, Ha H, Kim H
Scientific Reports 2018;8(1)

---

Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease.

Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, Ashley N, Cubitt L, Mellado-Gomez E, Attar M, Sharma E, Wills Q, Bowden R, Richter FC, Ahern D, Puri KD, Henault J, Gervais F, Koohy H, Simmons A
Cell 2018 Oct 4;175(2):372-386.e17

---

SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma.

Puglisi R, Bellenghi M, Pontecorvi G, Gulino A, Petrini M, Felicetti F, Bottero L, Mattia G, Carè A
Oncotarget 2018 Jan 26;9(7):7567-7581

---

miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo

Liang Z, Chen Y, Zhao Y, Xu C, Zhang A, Zhang Q, Wang D, He J, Hua W, Duan P
Stem Cell Research & Therapy 2017;8(1)

---

Cell-Type-Specific Chromatin States Differentially Prime Squamous Cell Carcinoma Tumor-Initiating Cells for Epithelial to Mesenchymal Transition

Latil M, Nassar D, Beck B, Boumahdi S, Wang L, Brisebarre A, Dubois C, Nkusi E, Lenglez S, Checinska A, Vercauteren Drubbel A, Devos M, Declercq W, Yi R, Blanpain C
Cell Stem Cell 2017;20(2):191-204.e5

---

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression

Denecker G, Vandamme N, Akay Ö, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi G, Rafferty M, Balint B, Gallagher W, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine J, Berx G
Cell Death & Differentiation 2014;21(8):1250-1261

---

Protein Expression of ZEB2 in Renal Cell Carcinoma and Its Prognostic Significance in Patient Survival

Prokunina-Olsson L, Fang Y, Wei J, Cao J, Zhao H, Liao B, Qiu S, Wang D, Luo J, Chen W
PLoS ONE 2013;8(5):e62558

---

Overexpression of ZEB2 in Peritumoral Liver Tissue Correlates with Favorable Survival after Curative Resection of Hepatocellular Carcinoma

Munshi H, Cai M, Luo R, Chen J, Pei X, Lu J, Hou J, Yun J
PLoS ONE 2012;7(2):e32838

---

Extensive expression of craniofacial related homeobox genes in canine mammary sarcomas

Wensman H, Göransson H, Leuchowius K, Strömberg S, Pontén F, Isaksson A, Rutteman G, Heldin N, Pejler G, Hellmén E
Breast Cancer Research and Treatment 2008;118(2):333-343

Chromatin Immunoprecipitation

Supportive validation

Submitted by

Atlas Antibodies (provider)

Main image

Experimental details

ChIP-Exo-Seq composite graph for Anti-ZEB2 (HPA003456, Lot 000044709) tested in K562 cells. Strand-specific reads (blue: forward, red: reverse) and IgG controls (black: forward, grey: reverse) are plotted against the distance from a composite set of reference binding sites. The antibody exhibits robust target enrichment compared to a non-specific IgG control and precisely reveals its structural organization around the binding site. Data generated by Prof. B. F. Pugh´s Lab at Cornell University.